

SABCS Disclosure Report
2010

Program #	Title	F. Name	L. Name	Disclosure Information
General Session 1 Moderator/Committee Member	N/A	Kathy	Albain	Dr. Albain has disclosed that she is a consultant/advisor for Genentech and Roche. She also disclosed that she is a meeting participant/lecture for Genomic Health and Agendia and does scientific study/trial for Merck.
Poster Discussion 4 Discussant	N/A	Catherine	Alix-Panabières	Dr. Alix-Panabieres has no relevant financial relationships to disclose.
Committee Member	N/A	William	Anderson	Dr. Anderson has no relevant financial relationships to disclose.
Plenary Speaker	The Upside of Irrationality	Dan	Ariely	Dr. Ariely has no relevant financial relationships to disclose.
Committee Member	N/A	Mark	Arredondo	Dr. Arredondo has disclosed that he is a meeting participant/lecture for Sanofi-Aventis.
Committee Member	N/A	Carlos	Arteaga	Dr. Arteaga has no relevant financial relationships to disclose.
Committee Member	N/A	Banu	Arun	Information not provided at this time.
AACR Distinguished Lectureship in Breast Cancer Research Speaker	Synthetic Lethal Approaches to Cancer Therapy	Alan	Ashworth	Dr. Ashworth has disclosed that he is a consultant/advisor for GSK. He also disclosed that he may benefit financially from the development of PARP inhibitors through patents held jointly with Astra-Zeneca through the Institute of Cancer Research "Rewards To Inventors" scheme.
Poster Discussion 7 Discussant	N/A	Jose	Baselga	Dr. Baselga has disclosed that he is a consultant/advisor for Merck and Exelixis.
Committee Member	N/A	Christopher	Benz	Dr. Benz has no relevant financial relationships to disclose.
Committee Member	N/A	Kimberly	Blackwell	Dr. Blackwell has disclosed that she is a consultant/advisor for Novartis, Sanofi-Aventis and Genentech. She has also disclosed she is an investigator for Genentech, Abraxis, BMS and GSK. Dr. Blackwell also disclosed that she is a meeting participant/lecture for Novartis, Sanofi-Aventis and GSK.
Committee Member	N/A	Powel	Brown	Dr. Brown has disclosed that he is a consultant/advisor for Susan G. Komen for the Cure Scientific Advisory Board.
Mini-Symposia "noncodingRNA- The New Frontier" Speaker	MicroRNA in medical practice	George A.	Calin	Dr. Calin has no relevant financial relationships to disclose.
The Year in Review Speaker/General Session 1 Moderator	Progress in advanced breast cancer	Lisa A.	Carey	Dr. Carey has disclosed that she is a consultant/advisor for Sanofi-Aventis, BiPar, Wyeth, Pfizer, Genentech, BMS and Novartis. She has also disclosed that she receives research support from GSK, Boehringer-Ingelheim, Genentech, Wyeth and BMS. Dr. Carey does not receive any compensation.
Committee Member	N/A	Gary C.	Chamness	Dr. Chamness has no relevant financial relationships to disclose.

SABCS Disclosure Report
2010

Program #	Title	F. Name	L. Name	Disclosure Information
Committee Member	N/A	Eric	Chang	Dr. Chang has no relevant financial relationships to disclose.
Mini-Symposia "noncodingRNA- The New Frontier" Speaker	Long noncoding RNAs in breast cancer progression	Howard Y.	Chang	Dr. Chang has no relevant financial relationships to disclose.
Committee Member	N/A	Jenny	Chang	Dr. Chang has no relevant financial relationships to disclose.
Committee Member/Poster Discussion 9 Discussant	N/A	Rowan	Chlebowski	Dr. Chlebowski has disclosed that he is a consultant/advisor for Astra-Zeneca, Pfizer, Novartis, Agendia and Genomic Health. He has also disclosed that he is a meeting participant/lecturer for Astra-Zeneca, Novartis and Agendia and does scientific study/trial for Amgen.
Basic Science Fourm "Breast Cancer Recurrence and Tumor Dormancy - What is it? Does it matter?" Moderator and Speaker	Models to mechanisms: Understanding tumor dormancy and breast cancer recurrence	Lewis A.	Chodosh	Dr. Chodosh has disclosed he served as an expert witness for defense counsel in litigation regarding Hormone Replacement Therapy.
Basic Science Forum "Stem Cells- Defying Definition?" Speaker	Stem cells and cancer, 2 faces of self renewal	Michael F.	Clarke	Dr. Clarke has disclosed that he is a consultant/advisor for Oncomed Pharmaceuticals. He has also disclosed that he has investment interest with Oncomed Pharmaceuticals-Equity .
Educational Session "CNS Metastases in Breast Cancer: Current Challenges and Future Directions" Speaker	Advances in neurosurgery in the management of CNS metastases	Elizabeth B.	Claus	Dr. Claus has no relevant financial relationships to disclose.
The Year in Review Speaker/General Session 2 Moderator	Early breast cancer	Alan	Coates	Dr. Coates has no relevant financial relationships to disclose.
General Session 5 Moderator	N/A	Hiram S.	Cody III	Dr. Cody, III has no relevant financial relationships to disclose.
Poster Discussion 9 Discussant	N/A	Graham	Colditz	Dr. Colditz has no relevant financial relationships to disclose.
Committee Member	N/A	Charles A	Coltman, Jr.	Dr. Coltman has disclosed that he is a consultant/advisor for Seno Medical.
Educational Session "Emerging Radiation Techniques – The Fast and the Furious" Moderator and Speaker/Committee Member/Case Discussion 2 Panelist	Radiosurgery and stereotactic body radiotherapy	Richard L.	Crownover	Dr. Crownover has no relevant financial relationships to disclose.
Plenary Speaker	Metabolic Reprogramming of Cancer Cells and Therapeutic Opportunities	Chi Van	Dang	Dr. Dang has disclosed that he is a consultant/advisor with Agios Pharmaceuticals, Inc.
Educational Session "The Clinical Utility of Genetic Testing for Inherited Predisposition to Breast Cancer: BRCA and Beyond" Speaker	Management of women with a highly penetrant predisposition to breast cancer: State of the art 2010	Susan M.	Domchek	Dr. Domchek has also disclosed that she does scientific study/trials for Astra-Zeneca on PARP inhibitors.

SABCS Disclosure Report
2010

Program #	Title	F. Name	L. Name	Disclosure Information
Educational Session Moderator/The Year in Review Speaker/Committee Member	Design & Interpretation of Biomarker Studies/Translational breast cancer research	Mitchell	Dowsett	Dr. Dowsett has disclosed that he is a consultant/advisor for AstraZeneca, Novartis and Roche. He has also disclosed that he is a meeting participant/lecturer for AstraZeneca and Roche, he does scientific study/trials for AstraZeneca, Novartis, and Roche and he is an advisory board member for AstraZeneca, Novartis, Roche and GSK.
Committee Member	N/A	Matthew	Ellis	Dr. Ellis has disclosed that he is a consultant/advisor for Novartis, AstraZeneca, Pfizer, Merck, GlaxoSmithKline and Genentech. He has also disclosed that he is a meeting participant/lecturer for Novartis, AstraZeneca, Pfizer, GlaxoSmithKline and Genentech. Dr. Ellis has disclosed that he does scientific study/trials for Novartis, AstraZeneca, Taiho and GlaxoSmithKline. Dr. Ellis also he receives grant support from Novartis. University Genomics holds the patent for Dr. Ellis patient care. Dr. Ellis has disclosed he has a license of PAM50 with Bioclassifier LLC.
Committee Member	N/A	Igor	Espinoza-Delgado	Dr. Espinoza-Delgado has no relevant financial relationships to disclose.
Educational Session Moderator/Clinical Science Froum "Controversies in Screening for Breast Cancer" Speaker/Committee Member	Symptom Management/Rethinking and Improving Screening in the Context of Breast Cancer Biology	Laura J.	Esserman	Dr. Esserman has no relevant financial relationships to disclose.
Committee Member	N/A	Carol	Fabian	Dr. Fabian has no relevant financial relationships to disclose.
Educational Session "Systems Biology – Can it Explain Everything?" Speaker	Systems biology for the clinician	Dana	Faratian	Dr. Faratian has no relevant financial relationships to disclose.
Clinical Science Froum "Controversies in Screening for Breast Cancer" Speaker	Breast cancer screening – The radiology perspective	Christopher I.	Flowers	Dr. Flowers has no relevant financial relationships to disclose.
Educational Session "DNA Repair" Speaker	DNA repair pathways and tumorigenesis	James M.	Ford	Dr. Ford has no relevant financial relationships to disclose.
Committee Member	N/A	Margaret	Foti	Dr. Foti has no relevant financial relationships to disclose.
The Year in Review Speaker/Committee Member	Advances in basic breast cancer research	Suzanne A.W.	Fuqua	Dr. Fuqua has no relevant financial relationships to disclose.
Educational Session "Next Generation Sequencing" Speaker	Leveraging next generation sequencing in the study of breast cancer somatic genetics	Andrew	Futreal	Dr. Futreal has no relevant financial relationships to disclose.
Committee Member	N/A	Patricia	Ganz	Dr. Ganz has no relevant financial relationships to disclose.
Clinical Science Froum "Controversies in Screening for Breast Cancer" Panelist	N/A	Judy E.	Garber	Dr. Garber has disclosed that she is a board member/officer/trustee for American Association for Cancer Research.

SABCS Disclosure Report
2010

Program #	Title	F. Name	L. Name	Disclosure Information
Committee Member	N/A	Luca	Gianni	Dr. Gianna has disclosed that he is a board member/officer/trustee for Istituto Nazionale Tumori as the Vice President. He has also disclosed that he is a consultant/advisor for Roche, Millennium, Eisai, Biogen, Sanofi and Novartis.
Committee Member	N/A	Stefan	Gluck	Dr. Gluck has disclosed that he is a consultant/advisor for Genentech, GSK, Novartis, and Abraxis. He has also disclosed that he is also an investigator for Genentech, GSK, Novartis, and Abraxis. Dr. Gluck is also a meeting participant/lecturer for Genentech, GSK, Novartis, and Abraxis. He has also disclosed that does scientific study/trials for Genentech, GSK, Novartis, and Abraxis.
Committee Member	N/A	Michael	Gnant	Dr. Gnant has disclosed that he is a consultant/advisor for Novartis, Amgen, AstraZeneca, Roche, and Sanofi-Aventis. He has also disclosed that he is a meeting participant/lecturer for Novartis, Amgen, Pfizer, Roche, Schering, Sanofi-Aventis and AstraZeneca.
General Session 1 Discussant/Committee Member	N/A	Matthew	Goetz	Dr. Goetz has no relevant financial relationships to disclose.
Committee Member	N/A	Ana Maria	Gonzalez-Angulo	Dr. Gonzalez-Angulo has no relevant financial relationships to disclose.
Poster Discussion 3 Discussant	N/A	Pamela	Goodwin	Dr. Goodwin has no relevant financial relationships to disclose.
General Session 2 Moderator/Committee Member	N/A	Paul	Goss	Dr. Goss has disclosed that he is on the speaker's bureau for Novartis, GSK and Pfizer.
Committee Member	N/A	M. Carolina	Gutierrez	Dr. Gutierrez has no relevant financial relationships to disclose.
Case Discussion 1 Panelist	N/A	Jay	Harris	Dr. Harris has no relevant financial relationships to disclose.
Committee Member	N/A	Lyndsay	Harris	Dr. Harris has no relevant financial relationships to disclose.
General Session 6 Moderator	N/A	Daniel	Hayes	Dr. Hayes has disclosed that he is a consultant/advisor for Compendia Biosciences and Chugai Pharmaceuticals. He is a meeting participant/lecturer for for Compendia Biosciences and Chugai Pharmaceuticals. He has also disclosed he is an investigator for GlaxoSmithKline, Pfizer, Novartis and Veridex (Johnson & Johnson). Dr. Hayes has an investment interest in Oncimmune LLC and Halcyon Diagnostics, Inc. stock.
Committee Member/Poster Discussion 8 Discussant	N/A	Dawn	Hershman	Dr. Hershman has no relevant financial relationships to disclose.
Committee Member	N/A	Bruce	Hillner	Dr. Hillner has no relevant financial relationships to disclose.

SABCS Disclosure Report
2010

Program #	Title	F. Name	L. Name	Disclosure Information
Committee Member	N/A	Susan G.	Hilsenbeck	Dr. Hilsenbeck has no relevant financial relationships to disclose.
Committee Member	N/A	Kathleen	Horst	Dr. Horst has no relevant financial relationships to disclose.
General Session 4 Moderator/Committee Member	N/A	Clifford	Hudis	Dr. Hudis has disclosed that he does scientific study/trials for Onyx (Sornfenb) and Merck (MK2206).
Case Discussion 1 Panelist	N/A	Kelly	Hunt	Dr. Hunt has no relevant financial relationships to disclose.
Poster Discussion 6 Discussant/Case Discussion 2 Panelist	N/A	E. Shelley	Hwang	Dr. Hwang has disclosed that she does scientific study/trials for Merck.
Committee Member	N/A	Debra	Ikeda	Dr. Ikeda has disclosed that she is an investigator for Aerospace Research Technologies, Inc.
Committee Member/Case Discussion 2 Panelist	N/A	James	Ingle	Dr. Ingle has disclosed that he is a consultant/advisor for Wyeth and Pfizer. He has also disclosed that he does scientific study/trials for Wyeth and Pfizer.
Mini-Symposia Moderator/Committee Member	Surgery	Ismail	Jatoi	Dr. Jatoi has no relevant financial relationships to disclose.
Case Discussion 2 Panelist	N/A	Stephen	Johnston	Dr. Johnston has disclosed that he does have a financial relationship and will receive grant support for education.
Mini-Symposia "Breast Cancer Health Disparities" Speaker	The role of providers in breast cancer disparities	Nancy L.	Keating	Dr. Keating has no relevant financial relationships to disclose.
Committee Member	N/A	Seema	Khan	Dr. Khan has no relevant financial relationships to disclose.
Committee Member	N/A	Tari	King	Dr. King has no relevant financial relationships to disclose.
Committee Member	N/A	Ian	Krop	Dr. Krop has disclosed that he does scientific study/trials for Genetech/Roche.
Committee Member	N/A	Rakesh	Kumar	Dr. Kumar has no relevant financial relationships to disclose.
Committee Member	N/A	Charlotte	Kuperwasser	Dr. Kuperwasser has no relevant financial relationships to disclose.
Educational Session Moderator/Committee Member	Systems Biology – Can it Explain Everything?	Adrian V.	Lee	Dr. Lee has disclosed that he is a consultant/advisor for Pfizer, Hoffman La Roche, Bristol Myers Squibb and OSI. He also disclosed research funds with Pfizer, and Hoffman La Roche.
Committee Member	N/A	Jessica W. T.	Leung	Dr. Leung has no relevant financial relationships to disclose.
General Session 5 Moderator/Committee Member	N/A	Michael	Lewis	Dr. Lewis has disclosed that he does scientific study/trials for Infinity Pharmaceuticals.
Committee Member	N/A	Rong	Li	Dr. Li has no relevant financial relationships to disclose.
Committee Member	N/A	Yi	Li	Dr. Li has no relevant financial relationships to disclose.
Poster Discussion 8 Discussant	N/A	Jennifer A.	Ligibel	Dr. Ligibel has no relevant financial relationships to disclose.

SABCS Disclosure Report
2010

Program #	Title	F. Name	L. Name	Disclosure Information
Educational Session "CNS Metastases in Breast Cancer: Current Challenges and Future Directions" Moderator and Speaker	Systemic therapy for CNS metastases	Nancy U.	Lin	Dr. Lin has disclosed that she does scientific study/trials for Glaxo Smith Kline, Genentech and Bayer.
Basic Science Forum "Stem Cells- Defying Definition?" Speaker/Poster Discussion 2 Discussant	Understanding stem cells to get abreast of breast cancer	Geoffrey	Lindeman	Dr. Linderman has disclosed that he is a consultant/advisor for Sanofi-Aventis.
Poster Discussion 4 Discussant	N/A	Minetta C.	Liu	Dr. Liu has disclosed that she is a consultant/advisor for Agendia, Genentech/Roche, Myriad Genetic Laboratories, Pfizer and Veridex, LLC. She has also disclosed that she is an investigator for Abraxis Oncology, Accelerated Community Oncology Research Network, Amgen, BiPAR, Bristol Myers Squibb, Genentech/Roche, GlaxoSmithKline, Novartis, and Veridex, LLC. Dr. Liu has disclosed that she is a meeting participant/lecturer for AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, and Veridex, LLC. She has also disclosed she does not receive any direct salary or royalties from, nor does she own any directly purchased stock in any corporate organization.
Committee Member	N/A	Charles	Loprinzi	Dr. Loprinzi has no relevant financial relationships to disclose.
Committee Member	N/A	Anthony	Lucci	Dr. Lucci has no relevant financial relationships to disclose.
Committee Member	N/A	Janice	Lyons	Information not provided at this time.
Committee Member	N/A	David	Mankoff	Dr. Mankoff has also disclosed that he is a consultant/advisor for Pfizer. He has also disclosed that he does scientific study/trials for Merck, and Pfizer.
Committee Member	N/A	Paul Kelly	Marcom	Dr. Marcom has no relevant financial relationships to disclose.
Educational Session "Next Generation Sequencing" Speaker	Next-generation sequencing and analysis of tumor/normal pairs	Elaine R.	Mardis	Dr. Mardis has disclosed that she is a board member/officer/trustee for Applied Biosystems Inc. (former board of directors). She has also disclosed that she is a consultant/advisor for Pacific Biosciences Inc. Dr. Mardis has an investment interest in Applied Biosystems/Lifetechno Logies stock and is also a meeting participant/lecturer for Illumina Inc. She also disclosed that she receives honoraria from Illumina Inc. and is paid to lecture by them.
Committee Member	N/A	Musa	Mayer	Dr. Mayer has disclosed that she does scientific study/trials for Genentech (unpaid) and Pfizer (receives a travel stipend otherwise unpaid).

SABCS Disclosure Report
2010

Program #	Title	F. Name	L. Name	Disclosure Information
Educational Session "Design & Interpretation of Biomarker Studies" Speaker	Statistical challenges in predictive and prognostic biomarker studies: How to avoid wasting your time and specimens	Lisa M.	McShane	Dr. McShane has no relevant financial relationships to disclose.
Educational Session "CNS Metastases in Breast Cancer: Current Challenges and Future Directions" Speaker	Radiation therapy for CNS metastases: What should the standard approach be?	Minesh P.	Mehta	Dr. Mehta has disclosed that he is a board member/officer/trustee for Pharmacyclics. He has also disclosed that he is a consultant/advisor for Schering Plough (Merck), Genentech, TomoTherapy, Adnexus and Bayer. Dr. Mehta has investment interests in Pharmacyclics and TomoTherapy.
Educational Session "Symptom Management" Speaker	Losing your hair during chemotherapy may not be inevitable: emerging techniques to avoid hair loss	Michelle	Melisko	Dr. Melisko has no relevant financial relationships to disclose.
Committee Member	N/A	Funda	Meric-Bernstam	Dr. Meric-Bernstam has disclosed that he is a board member/officer/trustee for Myriad Scientific Advisory.
Committee Member	N/A	Kathy	Miller	Dr. Miller had disclosed that she is a consultant/advisor and a meeting participant/lecturer for Genentech and Roche. She has also disclosed that she does scientific study/trials for Genentech, Roche, Amgen, Pfizer, BiPar, Geron and Imclone.
Committee Member	N/A	William	Miller	Dr. Miller has no relevant financial relationships to disclose.
Committee Member	N/A	Mark	Moasser	Dr. Moasser has no relevant financial relationships to disclose.
Committee Member	N/A	Susan	Mooberry	Dr. Mooberry has no relevant financial relationships to disclose.
Committee Member	N/A	Monica	Morrow	Dr. Morrow has no relevant financial relationships to disclose.
Committee Member	N/A	Pamela	Munster	Dr. Munster has no relevant financial relationships to disclose.
Mini-Symposia "Surgery" and "Breast Cancer Health Disparities" Speaker	Surgical considerations in early-stage breast cancer/African ancestry and high-risk breast cancer	Lisa A.	Newman	Dr. Newman has no relevant financial relationships to disclose.
Committee Member	N/A	Ruth	O'Regan	Dr. O'Regan has disclosed that she was a one time consultant/advisor in 2009 for Abraxis . She has also disclosed that she does scientific study/trials for Genentech, Pfizer, Abraxis and Novartis.
Basic Science Forum Moderator/The Year in Review Moderator/Committee Member	Managing Stress in Cancer Cells: New Druggable Pathways and Targets	C. Kent	Osborne	Dr. Osborne has disclosed that he is a consultant/advisor for Onyx Pharmaceuticals.
AACR Outstanding Investigator Award Speaker	Micrometastasis and dormancy in cancer patients	Klaus	Pantel	Dr. Pantel has no relevant financial relationships to disclose.
Brinker Award Speaker		Soonmyung "Soon"	Paik	Dr. Paik has no relevant financial relationships to disclose.

SABCS Disclosure Report
2010

Program #	Title	F. Name	L. Name	Disclosure Information
General Session 3 Moderator	N/A	Mark	Pegram	Dr. Pegram has disclosed that he is a board member/officer/trustee for TAKEDA and SFO. He has also disclosed that he is a consultant/advisor for GSK, Sanofi-Aventis, Genentech and AstraZeneca. Dr. Pegram has also disclosed that he does scientific study/trials for Sanofi-Aventis and AstraZeneca.
Committee Member	N/A	Edith	Perez	Dr. Perez has disclosed that she is an investigator for Genentech, Glaxo, sanofi-aventis, and research funding for Mayo Clinic.
Educational Session "Next Generation Sequencing for the Clinician" Moderator and Speaker/Committee Member	Next generation sequencing for gene expression profiling	Charles M.	Perou	Dr. Perou has disclosed that he is a consultant/advisor for Roche, Bristol Meyers Squibb, Eli Lilly and PharmaMar. He has also disclosed that he has an investment interest with University Genomics and Bioclassifier LLC. and he receives grant support from Roche, Bristol Meyers Squibb and Eli Lilly.
Mini-Symposia "Surgery" Speaker	Nipple sparing mastectomy with intra operative radiotherapy	Jean-Yves	Petit	Dr. Petit has no relevant financial relationships to disclose.
Committee Member	N/A	Martine	Piccart	Dr. Piccart has disclosed that she is a board member/officer/trustee for PharmaMar. She has also disclosed she is a consultant/advisor for Roche, Amgen, BMS, and Abraxis. Dr. Piccart has also disclosed she is also an investigator for MINDACT trial and ALTTO trial and does scientific study/trials. She also is a meeting participant/lecturer for Prime Oncology in San Antonio in a Satellite event.
Committee Member	N/A	Lori	Pierce	Dr. Pierce has no relevant financial relationships to disclose.
Educational Session "The Clinical Utility of Genetic Testing for Inherited Predisposition to Breast Cancer: BRCA and Beyond" Speaker	Evaluation of breast cancer predisposition in different clinical venues	Sharon E.	Plon	Dr. Plon has no relevant financial relationships to disclose.
Basic Science Forum "Managing Stress in Cancer Cells: New Druggable Pathways and Targets" Speaker	Cancers are stressed too: exploiting cancer stress for new therapies	Garth	Powis	Dr. Powis has disclosed that he is an employee of Phusis Therapeutics. He has also disclosed that he has an investment interest (stock) with Oncothyreon and Phusis Therapeutics
Committee Member	N/A	Kathleen	Pritchard	Dr. Pritchard has disclosed that she is a consultant/advisor for Roche, Abraxis, Boehringer-Ingelheim and Pfizer.
Educational Session "Design & Interpretation of Biomarker Studies" Speaker	Interpretation of biomarker studies	Lajos	Pusztai	Dr. Pusztai has no relevant financial relationships to disclose.
Educational Session "Symptom Management" Speaker	Long term management of pain due to, and after, primary treatment of breast cancer	Michael W.	Rabow	Dr. Rabow has no relevant financial relationships to disclose.
Committee Member	N/A	Susan	Rafte	Ms. Rafte has no relevant financial relationships to disclose.

SABCS Disclosure Report
2010

Program #	Title	F. Name	L.Name	Disclosure Information
Committee Member	N/A	Joseph	Ragaz	Ms. Ragaz has no relevant financial relationships to disclose.
Mini-Symposia Moderator	Breast Cancer Health Disparities	Amelie G.	Ramirez	Dr. Ramirez has no relevant financial relationships to disclose.
General Session 6 Moderator/Committee Member	N/A	Peter	Ravdin	Dr. Ravdin has disclosed that he is the owner of Adjuvent, Inc.
Educational Session "Design & Interpretation of Biomarker Studies" Speaker/Basic Science Forum Moderator/Poster Discussion 1 Discussant	The importance of technical validation/Stem Cells- Defying Definition?	Jorge	Reis-Filho	Dr. Reis-Filho has disclosed that he is the owner of Adjuvent, Inc.
Committee Member	N/A	Andrea	Richardson	Dr. Richardson has disclosed that she is a consultant/advisor for Genentech.
Committee Member/Case Discussion Moderator	N/A	Mothaffar	Rimawi	Dr. Rimawi has disclosed that he does scientific study/trials for GSK, Genentech, Pfizer, BMS and BIPAR.
Educational Session "Automated, Quantitative Cell and Tissue Imaging Technologies" Speaker	Quantitative methods to assess eligibility for breast cancer therapy	David L.	Rimm	Dr. Rimm has disclosed that he is a consultant/advisor for HistoRx and Metamark Genetics, Inc. He has also disclosed that he is a stockholder for HistoRx and Metamark Genetics, Inc.
Committee Member	N/A	Edgardo	Rivera	Dr. Rivera has no relevant financial relationships to disclose.
Educational Session "The Clinical Utility of Genetic Testing for Inherited Predisposition to Breast Cancer: BRCA and Beyond" Moderator and Speaker	Challenges to clinical application of new discoveries in the genetics of breast cancer predisposition	Mark E.	Robson	Dr. Robson has disclosed that he is a consultant/advisor with Pfizer Pharmaceuticals. He has also disclosed that he does scientific study/trials for Kudos Pharmaceuticals/AstraZeneca.
Brinker Award Speaker	Targeting of Breast Cancer Tumor Initiating Cells	Jeffrey M.	Rosen	Dr. Rosen has disclosed that he is a consultant/advisor for Macsogenics, Inc.
Poster Discussion 1 Discussant	N/A	Hope S.	Rugo	Dr. Rugo has disclosed that she is a meeting participant/lecturer for Novartis, Genomic Health, Eisai, Boehringer Ingelheim. She also disclosed that she does scientific study/trial for Genentech, Roche, BMS, GSK, Pfizer, Novartis, Merck, Abbott, and Abraxis (CALGB).
Case Discussion 2 Panelist	N/A	Ivis	Febus-Sampayo	Dr. Febus-Sampayo has no relevant financial relationships to disclose.
Committee Member	N/A	Otto	Sanchez	Information not provided at this time.
Educational Session Moderator/Committee Member/Poster Discussion 1 Discussant/General Session 3 Moderator	Automated, Quantitative Cell and Tissue Imaging Technologies	Rachel	Schiff	Dr. Schiff has disclosed that she does scientific study/trials for AstraZeneca, BMS, Lilly and GSK and receives research grants from them.
Educational Session "Symptom Management" Speaker	Balancing risks of deconditioning vs. Weight-lifting for breast cancer survivors for Lymphedema	Kathryn h.	Schmitz	Dr. Schmitz has no relevant financial relationships to disclose.
Case Discussion 1 Panelist	N/A	Emily	Sedgwick	Dr. Sedgwick has no relevant financial relationships to disclose.
Case Discussion 1 Panelist	N/A	Karla	Sepulveda	Dr. Sepulveda has no relevant financial relationships to disclose.

SABCS Disclosure Report
2010

Program #	Title	F. Name	L.Name	Disclosure Information
Educational Session "DNA Repair" Moderator and Speaker	DNA repair and breast cancer: Therapeutic opportunities and challenges	Daniel P.	Silver	Dr. Silver has disclosed that he is a consultant/advisor for Genentech and Inotek Pharmaceuticals.
Committee Member	N/A	Melvin	Silverstein	Information not provided at this time.
William L. McGuire Memorial Lecture	What Would Bill Do? Channeling Your Inner McGuire	George W.	Sledge, Jr.	Dr. Sledge has no relevant financial relationships to disclose.
Committee Member	N/A	Ian	Smith	Dr. Smith has disclosed that he is a consultant/advisor for Roche, sanofi-aventis and Bayer. Dr. Smith has also disclosed he is a meeting participant/lecturer for Roche, GSK and sanofi-aventis.
Educational Session "Automated, Quantitative Cell and Tissue Imaging Technologies" Speaker and Educational Session "Systems Biology – Can it Explain Everything?" Speaker	Measuring and modeling cell death pathways in tumor cells/Cancer systems biology: Concepts and perspectives?	Peter K.	Sorger	Dr. Sorger has disclosed that he is a board member/officer/trustee for Applied Precision Inc. He has also disclosed that he is a consultant/advisor for Boehringer Ingelheim Inc. Dr. Sorger also is owner of Merrimack Pharmaceuticals and Glencoe Software.
Committee Member	N/A	Christos	Sotiriou	Dr. Sotiriou has no relevant financial relationships to disclose.
Plenary Speaker	Drug Development – Targeting HER2 Beyond Trastuzumab	Neil	Spector	Dr. Spector has disclosed that he is a consultant/advisor with Millennium/Takeda.
Educational Session "Systems Biology – Can it Explain Everything?" Speaker	Modeling sensitivity to therapeutic agents	Paul T.	Spellman	Dr. Spellman has disclosed that he does scientific study/trials for GSK.
Poster Discussion 3 Discussant	N/A	Vuk	Stambolic	Dr. Stambolic has no relevant financial relationships to disclose.
Committee Member	N/A	Sandi	Stanford	Dr. Stanford has no relevant financial relationships to disclose.
Educational Session "CNS Metastases in Breast Cancer: Current Challenges and Future Directions" Speaker and Basic Science Froum "Breast Cancer Recurrence and Tumor Dormancy - What is it? Does it matter?" Speaker	Translating new approaches from bench to bedside/Preclinic imaging of metastasis and dormancy: Clinical implications	Patricia S.	Steeg	Dr. Steeg has disclosed that she receives research support from GSK and Millenium.
Mini-Symposia Moderator/Committee Member	noncodingRNA- The New Frontier	Saraswati	Sukumar	Dr. Sukumar has disclosed that she is a consultant/advisor with Susan G. Komen FDN on their scientific advisory board.
Clinical Science Froum "Controversies in Screening for Breast Cancer" Panelist	N/A	Chris	Tannous	Dr. Tannous has no relevant financial relationships to disclose.
Committee Member	N/A	Elizabeth	Thompson	Ms. Thompson has disclosed that she is an employee of Susan G. Komen for the Cure.
Committee Member	N/A	Ian	Thompson	Dr. Thompson has disclosed that he is a board member/officer/trustee for Mission Pharmacal. He has also disclosed that he is a consultant/advisor with Veridex (Johnson & Johnson) and he is an investigator for NIH.

SABCS Disclosure Report
2010

Program #	Title	F. Name	L.Name	Disclosure Information
Educational Session "Symptom Management" Speaker	Understanding the role of botanicals in the management of breast cancer	Debasish	Tripathy	Dr. Tripathy has no relevant financial relationships to disclose.
General Session 4 Moderator	N/A	Nicholas	Turner	Dr. Turner has disclosed that he is a consultant/advisor for Novartis, AstraZeneca and Pfizer. Dr. Turner has also disclosed that he is an investigator for Novartis, AstraZeneca and Roche. He also does scientific study/trials for AstraZeneca.
Mini-Symposia "Surgery" Speaker	Recent U.S. trends in the local treatment of primary breast cancer	Todd M.	Tuttle	Dr. Tuttle has no relevant financial relationships to disclose.
Committee Member	N/A	Naoto	Ueno	Dr. Ueno has disclosed that he is a consultant/advisor with Syndex Pharma and Kyowa-Kirm. He has also disclosed that he does scientific study/trial for Amgen and Abraxis Bio.
Committee Member	N/A	Vincente	Valero	Dr. Valero has no relevant financial relationships to disclose.
Poster Discussion 10 Discussant	N/A	Giuseppe	Viale	Dr. Viale has disclosed that he is a consultant/advisor for Dako and Denmark. He has also disclosed he is a meeting participant/lecturer for Dako and Denmark.
Educational Session "Emerging Radiation Techniques – The Fast and the Furious" Speaker	Rationale and results of accelerated partial breast irradiation	Frank A.	Vicini	Dr. Vicini has no relevant financial relationships to disclose.
Mini-Symposia "Breast Cancer Health Disparities" Speaker	Advance in breast cancer risk assessment screening and prevention: Adapting the lessons to an underserved Latin population	Jeffrey N.	Weitzel	Dr. Weitzel has no relevant financial relationships to disclose.
Case Discussion 1 Panelist	N/A	Kathleen	Werner	Dr. Werner has no relevant financial relationships to disclose.
Poster Discussion 6 Discussant	N/A	Julia	White	Dr. White has no relevant financial relationships to disclose.
General Session 3 Discussant/Clinical Science Forum Moderator/Committee Member/Case Discussion 1 Panelist	Controversies in Screening for Breast Cancer	Eric P.	Winer	Dr. Winer has no relevant financial relationships to disclose.
Committee Member/Case Discussion 1 Panelist	N/A	Antonio	Wolff	Dr. Wolff has disclosed that he does scientific study/trial for Genentech.
Basic Science Forum "Managing Stress in Cancer Cells: New Druggable Pathways and Targets" Speaker	Molecular chaperones: Cancer dependence and druggability	Paul	Workman	Dr. Workman has disclosed that he is a consultant/advisor for Chroma Therapeutics; formerly Piramed. He has also disclosed that he has investment interest with Chroma Therapeutics; formerly Piramed. He has also disclosed that he has received previous funding from Vevnatis; Hsp90 inhibitors licensed to Novartis.
Committee Member	N/A	Wei	Yang	Dr. Yang has no relevant financial relationships to disclose.

SABCS Disclosure Report
2010

Program #	Title	F. Name	L.Name	Disclosure Information
Committee Member	N/A	Douglas	Yee	Dr. Yee has disclosed that he is a consultant/advisor for Komen for the Cure.
Committee Member	N/A	Richard	Zellars	Dr. Zellars has no relevant financial relationships to disclose.